{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:00:59Z","timestamp":1789736459027,"version":"4.0.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institute of Pharmaceutical Education and Research, Hyderabad and Department of Biotechnology Government of India"},{"name":"Department of Pharmaceuticals, Ministry of chemical and fertilizers and NIPER Hyderabad","award":["BT\/527\/NE\/TBP\/2013"],"award-info":[{"award-number":["BT\/527\/NE\/TBP\/2013"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.neuropharm.2016.09.027","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T09:10:12Z","timestamp":1475831412000},"page":"137-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"PA","title":["Combination strategy of PARP inhibitor with antioxidant prevent bioenergetic deficits and inflammatory changes in CCI-induced neuropathy"],"prefix":"10.1016","volume":"113","author":[{"given":"Prashanth","family":"Komirishetty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Areti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranadeep","family":"Gogoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramakrishna","family":"Sistla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6659-4751","authenticated-orcid":false,"given":"Ashutosh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.neuropharm.2016.09.027_bib1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2174\/1570159X14666151126215358","article-title":"Potential therapeutic benefits of maintaining mitochondrial health in peripheral neuropathies","volume":"14","author":"Areti","year":"2015","journal-title":"Curr. neuropharmacol."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejphar.2008.08.003","article-title":"Amelioration of neurological and biochemical deficits by peroxynitrite decomposition catalysts in experimental diabetic neuropathy","volume":"596","author":"Arora","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1744-8069-9-53","article-title":"The antioxidant effects of the flavonoids rutin and quercetin inhibit oxaliplatin-induced chronic painful peripheral neuropathy","volume":"9","author":"Azevedo","year":"2013","journal-title":"Mol. pain"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00006534-198901000-00024","article-title":"Functional evaluation of complete sciatic, peroneal, and posterior tibial nerve lesions in the rat","volume":"83","author":"Bain","year":"1989","journal-title":"Plastic Reconstr. Surg."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.bbr.2009.07.005","article-title":"Chronic restraint stress induces mechanical and cold allodynia, and enhances inflammatory pain in rat: relevance to human stress-associated painful pathologies","volume":"205","author":"Bardin","year":"2009","journal-title":"Behav. brain Res."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3959(88)90209-6","article-title":"A\u00a0peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man","volume":"33","author":"Bennett","year":"1988","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib7","first-page":"19","article-title":"Review: from nociception to pain perception: imaging the spinal and supraspinal pathways","volume":"207","author":"Brooks","year":"2005","journal-title":"J.\u00a0Anat."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jss.2013.02.016","article-title":"Beneficial effects of quercetin on rat urinary bladder after spinal cord injury","volume":"183","author":"Cevik","year":"2013","journal-title":"J.\u00a0Surg. Res."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib9","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0885-3924(03)00064-2","article-title":"Diagnosis and treatment of neuropathic pain","volume":"25","author":"Chong","year":"2003","journal-title":"J.\u00a0pain symptom Manag."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib10","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1089\/ars.2012.4981","article-title":"Traumatic brain injury: oxidative stress and neuroprotection","volume":"19","author":"Cornelius","year":"2013","journal-title":"Antioxidants redox Signal."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1742-2094-9-31","article-title":"Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor","volume":"9","author":"Da Avila","year":"2012","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.neuint.2015.07.002","article-title":"Quercetin in brain diseases: potential and limits","volume":"89","author":"Dajas","year":"2015","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0304-3959(98)00044-X","article-title":"Intrathecal implants of bovine chromaffin cells alleviate mechanical allodynia in a rat model of neuropathic pain","volume":"76","author":"Decosterd","year":"1998","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/bja\/aen107","article-title":"Neuropathic pain: emerging treatments","volume":"101","author":"Dray","year":"2008","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib15","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1210\/en.2009-1342","article-title":"New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-a","volume":"151","author":"Drel","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: evidence-based recommendations","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1124\/jpet.104.076711","article-title":"Inhibitors of poly (ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma","volume":"312","author":"Genovese","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1124\/jpet.104.076711","article-title":"Inhibitors of poly (ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma","volume":"312","author":"Genovese","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib19","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.bcp.2010.04.022","article-title":"PARP inhibitors: new tools to protect from inflammation","volume":"80","author":"Giansanti","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1586\/14737175.5.6.823","article-title":"Combination pharmacotherapy for neuropathic pain: current evidence and future directions","volume":"5","author":"Gilron","year":"2005","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib21","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1007\/s00018-002-8527-2","article-title":"The functional role of poly (ADP-ribose) polymerase 1 as novel coactivator of NF-kB in inflammatory disorders","volume":"59","author":"Hassa","year":"2002","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib22","series-title":"PARP and the Release of Apoptosis-inducing Factor from Mitochondria. Poly (ADP-ribosyl) Ation","first-page":"103","author":"Hong","year":"2006"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.brainresbull.2004.01.006","article-title":"Attenuation of mechanical but not thermal hyperalgesia by electroacupuncture with the involvement of opioids in rat model of chronic inflammatory pain","volume":"63","author":"Huang","year":"2004","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejphar.2010.08.050","article-title":"Differential effect of spironolactone in chronic constriction injury and vincristine-induced neuropathic pain in rats","volume":"648","author":"Jaggi","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrd1718","article-title":"Poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors","volume":"4","author":"Jagtap","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0891-5849(90)90131-2","article-title":"Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury","volume":"9","author":"Janero","year":"1990","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.freeradbiomed.2015.03.035","article-title":"The involvement of p62-Keap1-Nrf2 antioxidative signaling pathway and JNK in the protection of natural flavonoid quercetin against hepatotoxicity","volume":"85","author":"Ji","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.brainresbull.2003.11.001","article-title":"Neuroprotective effect of 4-amino-1, 8-napthalimide, a poly (ADP ribose) polymerase inhibitor in middle cerebral artery occlusion-induced focal cerebral ischemia in rat","volume":"62","author":"Kabra","year":"2004","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib29","first-page":"1","article-title":"Morin mitigates chronic constriction injury (CCI)-Induced peripheral neuropathy by inhibiting oxidative stress induced PARP over-activation and neuroinflammation","author":"Komirishetty","year":"2016","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lfs.2016.02.085","article-title":"PARP inhibition attenuates neuroinflammation and oxidative stress in chronic constriction injury induced peripheral neuropathy","volume":"150","author":"Komirishetty","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib31","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1471-4159.2007.05114.x","article-title":"Identification of poly-ADP-ribosylated mitochondrial proteins after traumatic brain injury","volume":"104","author":"Lai","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib32","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1471-4159.2007.05114.x","article-title":"Identification of poly (ADP) ribosylated mitochondrial proteins after traumatic brain injury","volume":"104","author":"Lai","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12990-015-0057-7","article-title":"Mitochondrial and bioenergetic dysfunction in trauma-induced painful peripheral neuropathy","volume":"11","author":"Lim","year":"2015","journal-title":"Mol. pain"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib34","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.4314\/tjpr.v13i9.26","article-title":"Pharmacological applications of quercetin and its derivatives: a short review","volume":"13","author":"Maalik","year":"2014","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1357-4310(00)01814-1","article-title":"NF-kB as a therapeutic target in chronic inflammation: recent advances","volume":"6","author":"Makarov","year":"2000","journal-title":"Mol. Med. today"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib36","first-page":"51","article-title":"The effect of the flavonoid quercetin on pain sensation in diabetic rats","volume":"2","author":"Narenjkar","year":"2011","journal-title":"Basic Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib37","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.neuropharm.2009.11.018","article-title":"Functional and biochemical evidence indicating beneficial effect of Melatonin and Nicotinamide alone and in combination in experimental diabetic neuropathy","volume":"58","author":"Negi","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bbrc.2009.11.010","article-title":"Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy","volume":"391","author":"Negi","year":"2010","journal-title":"Biochem. biophysical Res. Commun."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1600-079X.2010.00821.x","article-title":"Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kB and Nrf2 cascades","volume":"50","author":"Negi","year":"2011","journal-title":"J.\u00a0pineal Res."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib42","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2337\/diabetes.53.3.711","article-title":"Role of poly (ADP-ribose) polymerase activation in diabetic neuropathy","volume":"53","author":"Obrosova","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib43","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.2337\/diabetes.54.12.3435","article-title":"Oxidative-nitrosative stress and poly (ADP-Ribose) polymerase (PARP) activation in experimental diabetic neuropathy the relation is revisited","volume":"54","author":"Obrosova","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib44","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.bbrc.2007.03.163","article-title":"Pharmacological inhibition of PARP-1 reduces alpha-synuclein-and MPP+-induced cytotoxicity in Parkinson's disease in\u00a0vitro models","volume":"357","author":"Outeiro","year":"2007","journal-title":"Biochem. biophysical Res. Commun."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.freeradbiomed.2009.04.008","article-title":"PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases","volume":"47","author":"Peralta-Leal","year":"2009","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1365-2710.2001.00355.x","article-title":"Pharmacology of oral combination analgesics: rational therapy for pain","volume":"26","author":"Raffa","year":"2001","journal-title":"J.\u00a0Clin. Pharm. Ther."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib47","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1152\/physrev.00011.2005","article-title":"Heme oxygenase-1\/carbon monoxide: from basic science to therapeutic applications","volume":"86","author":"Ryter","year":"2006","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib48","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/674987","article-title":"Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets","volume":"2014","author":"Sandireddy","year":"2014","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib49","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/abio.2002.5676","article-title":"Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy","volume":"306","author":"Sastry","year":"2002","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib50","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0003-2697(68)90092-4","article-title":"Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent","volume":"25","author":"Sedlak","year":"1968","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib51","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.lfs.2007.11.031","article-title":"Protective effects of 4-amino1, 8-napthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy","volume":"82","author":"Sharma","year":"2008","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib52","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/10715760902801509","article-title":"Neuroprotective potential of combination of resveratrol and 4-amino 1, 8 naphthalimide in experimental diabetic neuropathy: focus on functional, sensorimotor and biochemical changes","volume":"43","author":"Sharma","year":"2009","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib53","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/aps.2013.59","article-title":"Quercetin protects rat dorsal root ganglion neurons against high glucose-induced injury in\u00a0vitro through Nrf-2\/HO-1 activation and NF-kB inhibition","volume":"34","author":"Shi","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib54","doi-asserted-by":"crossref","unstructured":"Ta, L. E., Schmelzer, J. D., Bieber, A. J., Loprinzi, C. L., Sieck, G. C., Brederson, J. D., Low, P. A., Windebank, A. J., A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PloS one 8, e54161.","DOI":"10.1371\/journal.pone.0054161"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI11830","article-title":"NF-kB: a key role in inflammatory diseases","volume":"107","author":"Tak","year":"2001","journal-title":"J.\u00a0Clin. investigation"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib56","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/PHM.0b013e31815e6370","article-title":"The incidence of peripheral nerve injury in extremity trauma","volume":"87","author":"Taylor","year":"2008","journal-title":"Am. J. Phys. Med. Rehabilitation"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib57","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2016.09.027_bib58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biocel.2006.07.001","article-title":"Free radicals and antioxidants in normal physiological functions and human disease","volume":"39","author":"Valko","year":"2007","journal-title":"Int. J. Biochem. cell Biol."},{"key":"10.1016\/j.neuropharm.2016.09.027_bib59","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.redox.2013.07.005","article-title":"Potential therapeutic effects of the simultaneous targeting of the Nrf2 and NF-kB pathways in diabetic neuropathy","volume":"1","author":"Yerra","year":"2013","journal-title":"Redox Biol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816304373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390816304373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T16:32:34Z","timestamp":1718814754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390816304373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":57,"alternative-id":["S0028390816304373"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.09.027","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination strategy of PARP inhibitor with antioxidant prevent bioenergetic deficits and inflammatory changes in CCI-induced neuropathy","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}